Real-World Study of Efficacy, Risk Management and Reasons for Discontinuation of Natalizumab for Treatment of Multiple Sclerosis in Russia

PLoS ONE - United States
doi 10.1371/journal.pone.0217303
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Natalizumab Treatment in Multiple Sclerosis

Clinical Neurology
Neurology
2015English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

JAMA Neurology
Neurology
2013English

Clinical Effects of Natalizumab on Multiple Sclerosis Appear Early in Treatment Course

Journal of Neurology
Neurology
2013English

Evolution of MRI Appearances Due to Progressive Multifocal Leucoencephalopathy Following Natalizumab Treatment for Multiple Sclerosis

BMJ Case Reports
Medicine
2015English

Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

New England Journal of Medicine
Medicine
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy